

## **CONFERENCE PROGRAMME**

## Monday 27 November 2017

09:45 - 10:15	Press Conference	
10.15 - 11.15 Auditorium	Opening of EAPM European Union (EU) Presidency Congress	
10.15 - 10.20	Chair: Denis Horgan Executive Director, European Alliance for Personalised Medicine (EAPM) Brussels, Belgium	
10.20 - 10.30	Welcome: David Byrne Former European Commissioner for Health and Consumer Protection and Co-Chair EAPM, Brussels, Belgium	
10.30 - 10.40	Simon Harris Minister of Health, Republic of Ireland	
10.40 - 10.50	Jevgeni Ossinovski Minister of Health, Estonia	
10.50 - 11.00	Cristian Silviu Busoi Member of the European Parliament, Brussels, Belgium	
11.00 - 11.10	Hon. Christopher Fearne MP Deputy Prime Minister, Malta	
11:10 - 11:15	Q&A Discussion	



11.15 - 13:00 Auditorium Opening Plenary Presidential Session: Round Table "Growth in Personalised Healthcare
- The promise for future generations"

11.15 - 11.20 Chair: Mark Lawler

Chair in Translational Cancer Genomics, Centre for Cancer Research and Cell Biology(CCRCB), Queen's University Belfast, UK

11.20 - 11.35 Desmond Schatz

Associate Chairman of Pediatrics, School of Medicine University of Florida, Gainesville, Florida USA

11.35 - 11.50 Samuele Butera

Global Cell and Gene therapies Business Leader, Novartis, New York, USA

11.50 - 12.05 Peter Meeus

Head of Region Europe, Shire, London, UK

12.05 - 12.20 Transformation of Clinical Research: filling the gap between research and care towards new health care systems

enis Lacombe

Director General, European Organisation for Research and Treatment of Cancer, Brussels, Belgium

12.20 - 12.30 Chris Round

Head of EMEA Biopharma Global Commercial Operations, Merck

12.30 - 12.40 Lorraine Nolan

Chief Executive, Health Products Regulatory Authority, Dublin, Ireland


12.40 - 13.00 Q&A Discussion

13.00 - 13:45 Hall 1

**Lunch and Networking** 

















#### The Value of Sustainable Healthcare

Meeting Room	
13.45 - 13.50	Chair: Denis Horgan Executive Director, EAPM, Brussels, Belgium
13.50 - 14.05	Kim Stratton Head International Commercial, Shire, London, UK
14.05 - 14.20	The Value of Treatment Project: towards optimising care for brain disorders Giovanni Esposito European Brain Council, Brussels, Belgium
14.20- 14.35	The Value of Treatment Project: the economic evaluation and case studies analysis Michela Tinelli Department of Social Policy, London School of Economics, London, UK
14.35 - 14.50	The Value of Treatment Project: conclusions and policy recommendations Patrice Boyer President, European Psychiatric Association, Paris, France
14.50 - 15.00	EU added value in research for the benefit of patients Stéphane Hogan Head of Sector for Neuroscience, DG Research & Innovation, European Commission, Brussels, Belgium
15.00 - 15.10	Regualtory Angle Seamus Kearney CEO & Principal Consultant, ARC Regulatory, Magherafelt, UK
15.10 - 15.20	Natasha Azzopardi Muscat Consultant Public Health Medicine, Department for Public in Health, Health Information and Research, Valletta, Malta
15.20 - 15.30	Q&A
















## European Hematology Association Session – Personalising treatment of blood diseases – Taking advantage of the leukemia/lymphoma genome

13.45 - 13.55 Chair: Ulrich Jäger

Professor of Hematology, Medical University of Vienna, Austria

13.55 - 14.20 Personalisation in Hematology

Ulrich Jäger

Professor of Hematology, Medical University of Vienna, Austria

14.20 - 14.45 Carin Smand

Director, European Hematology Association (EHA), The Hague, The Netherlands

14.45 - 15.10 Access to Innovative Medicines

**Anton Hagenbeek** 

University of Amsterdam - Academic Medical Centre, The Netherlands

15.10 - 15.30 Round Table Discussion



### Capturing the Global Picture in Precision Medicine

3A 13.45 - 13.50

Chair: Richard Barker

Center for the Advancement of Sustainable Medical Innovation (CASMI), Oxford/University College London, UK

13.50 - 14.00

Mark Lawler

Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK

14.00 - 14.10

Genome Asia 100K for Precision Medicine

Lakshmi Santhosh

Project Director of Genome Asia 100K

14.10 - 14.20

**Vineet Datta** 

Executive Director, Datar Genetics Limited, New Delhi, India

14.20 - 14.35

Koen Block

Executive Director, European AIDS Treatment Group (EATG), Brussels, Belgium

14.35 - 14.50

Maarten IJzerman

Chair, Department of Health Technology & Services Research, University of Twente, Twente, Netherlands

14.50 - 15.05

IC-PerMed Perspective

Ain Aaviksoo

Deputy Secretary General for E-services and Innovation, Ministry of Social Affairs, Tallinn, Estonia

15.05 - 15.30 Round Table Discussion



## A Tale of Two Cities: a whole system approach to personalised medicine and health

Meeting Room 3B 13.45 - 13.50

Co-Chair: Gianni D'Errico

European Funding Officer, Regional Foundation for the Biomedical Research, Lombardy, Milan, Italy

13.50 - 13.55

Co-Chair: Michael Paul Messenger

Principal Healthcare Scientist, Leeds Institute of Cancer & Pathology, Leeds, UK

13.55 - 14.05

PPM+ The Leeds Care Record: Big Data supporting PM

**Geoff Hall** 

Chief Clinical Information Officer, Leeds Teaching Hospital NHS Trust, Leeds, UK

14.05 - 14.15

Early Health Economic Modelling - developing the evidence of value

**Bethany Shinkins** 

Test Evaluation Group Lead, University of Leeds, Leeds, UK

14.15 - 14.25

Management of people affected by chronic disease(s): A challenge to our society.

Paolo Mocarelli

Scientific Director of "don Gnocchi Foundation", Milan, Italy

14.25 - 14.40

Genomics and Big data, from science to medicine and back

Giovanni Tonon

Director, Centre for Translational Genomics and BioInformatics, San Raffaele Institute, Milan, Italy













14.40 - 14.55 Accelerating PM and Health - a whole system approach
Michael Paul Messenger
Principal Healthcare Scientist, Leeds Institute of Cancer & Pathology, Leeds, UK
 14.55 - 15.10 Public Consultation on Personalised Medicine in Lombardy Region.
Marina Gerini
Director General - Regional Foundation for Biomedical Research
 15.10 - 15.30 Round Table Discussion

15.30 - 17.10 Auditorium

#### Presidential Session - Shaping Future Healthcare and the One Health Agenda I

15.30 - 15.35 Co-Chair: Alastair Kent

Ambassador, Genetic Alliance, London, UK

15.35 - 15.45 Richard English

Pro-Vice-Chancellor for Internationalisation and Engagement, Queen's University Belfast, UK

15.45 - 16.00 Sue Hill, OBE

Chief Scientific Officer, NHS England, London, UK

16.00 - 16.15 Sir John Chisholm

Executive Chair, Genomics England, Cambridge, UK

16.15 - 16.30 Mark Caulfield

Chief Scientist, Genomics England, Cambridge, UK

16.30 - 16.40 Ian Young

Chief Scientific Advisor, Department of Health, Social Services and Public Safety, Belfast, Northern Ireland, UK

16.40 - 16.50 Mike Thompson

Chief Executive Officer, The Association of the British Pharmaceutical Industry, London, UK

16.50 - 17.10 Q&A Discussion

17.10 - 17:30 Hall 1

#### Coffee, Posters and Networking



**Auditorium** 

#### Presidential Session - Shaping Future Healthcare and the One Health Agenda II

17.30 - 17.35 Chair: Peter Hongaard Anderson

Innovation Fund, Copenhagen, Denmark

17.35 - 17.50 Scenario for the Danish healthcare system 2030

Bogi Eliasen

Futurist, Copenhagen Institute for Futures Studies, Copenhagen, Denmark

17.50 - 18.05 How do we sustain medical innovation?

**Richard Barker** 

Founding Director, Center for the Advancement of Sustainable Medical Innovation (CASMI), Oxford, UK

18.05 - 18.20 Designing a world where people get sick no more

**Koen Kas** 

CEO, InBio Veritas & Healthskouts; Professor of Biochemistry, University of Gent, Gent, Belgium

18.20 - 18.30 Q&A

	Special lecture
18.30 - 19.30 Auditorium	Chair: Gordon McVie Co-Chair EAPM, Brussels, Belgium
	Alexander Eggermont Director General, Institute Gustave Roussy, Paris, France
	Welcome Reception, Belfast City Hall (hosted by Lord Mayor)
	EAPM AWARD: 'Patient-centric Innovator Award' EAPM SMART AWARD: Smaller Members And Regions Together
19:45 - 22:00	David Byrne Former European Commissioner for Health and Consumer Protection and Co-Chair EAPM, Brussels, Belgium
	Right Honourable James Brokenshire Secretary of State, Northern Ireland











## **Tuesday 28 November 2017**



#### 08:15 - 10:00 Auditorium

#### **Presidential Session: Big Data Saves Lives**

08.15 - 08.20

Co-Chair: Mark Lawler

Chair in Translational Cancer Genomics, CCRCB Queen's University Belfast, UK and Co-Chair Clinical Cancer Genome Task Team, Global Alliance for Genomics and Health (GA4GH)

08.20 - 08.25 Co-Chair: Julia Wilso

Associate Director, Welcome Trust Sanger Centre Cambridge UK and Clinical Working Group, GA4GH

08.25 - 08.40 Gearing an entire country for Health Data Science

**Andrew Morris** 

Director Health Data Research UK, London, UK

08.40 - 08.55 Ewan Birney

Director European Bioinformatics Institute, Cambrdge UK and Chair, GA4GH

08.55 - 09.10 Mene Pangalos

Executive Vice President Innovative Medicines and Early Development Biotech Unit, AstraZeneca Cambridge, UK

09.10 - 09.20 Ain Aaviksoo

Deputy Secretary General for E-services and Innovation, Ministry of Social Affairs, Estonia

09.20 - 09.30 Data to the People - MIDATA Cooperatives

**Ernst Hafen** 

Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland

09.30 - 09.40 Margaret Grayson

Chair Northern Ireland Cancer Research Consumer Forum, Belfast, UK

09.40 - 10.00 Round Table Discussion

10:00 - 10:30 Hall 1	Coffee, Posters and Networking
10:00 - 10:30	Press Briefing Centre (The Studio)

### **Speed Networking (Hall 1)**

		· · · · · · · · · · · · · · · · · · ·			
	Meet the Cancer Patient	Meet the Business Leader	Meet the Cancer Research Expert	Meet the Policy Maker	Meet the Professor
10:00 - 10:30	<b>Ken Mastris</b> Chairman of the Board, Europa Uomo	<b>Peter Meeus</b> Head of Region Europe, Shire	Francoise Munier Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland	Ain Aaviksoo Deputy Secretary General for E-services and Innovation, Ministry of Social Affairs, Estonia	Mark Lawler Chair in Translational Cancer Genomics, Queen's University Belfast, UK
	Meet the Regional Expert	Meet the Diabetes Expert	Meet the Clinical Research Expert	Meet the Politician	Meet the Oncologist
	Gianni D'Enrico European Funding Officer, Regional Foundation for the Biomedical Research, Lombardy, Milan, Italy	<b>Jeannette Soderberg</b> Project Manager, JDRF	Denis Lacombe Director General, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium	Cristian Silviu Busoi Member of the European Parliament, Brussels, Belgium	Giovanni Codacci Pisanelli Assistant Professor in Medical Oncology, University of Rome "La Sapienza", Rome, Italy













## Solving the challenges for manufacturing personalised medicines at an industrial scale

10:30 - 12:10 The Studio

10.30 - 10.35 Chair: John Milne

Training Director, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland

10.35 - 10.50 Manufacturing processes of the future

John Milne

Training Director, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland

10.50 - 11.05 The future workforce

Killian O'Driscoll

Director of Projects at NIBRT, Dublin, Ireland

11.05 - 11.20 Andrew Whytock

Industry 4.0 and Digitalization lead, Pharmaceutical Business Segment, Siemens AG, Mannheim, Germany

11.20 - 11.35 Prof Kieran Hodnett

Scientific Director and Principal Investigator SSPC, University of Limerick, Limerick, Ireland

11.35 - 11.45 Key Challenges for the BioPharma Sector in Ireland

**Matt Moran** 

Director, BioPharmaChem Ireland, Dublin, Ireland

11.45- 12.10 Round Table



#### Ulster University Session on Precision Medicine in Multi-morbid Inflammatory Disease

10.30 - 10.35 Chair: Tony Bjourson

Director, Northern Ireland Centre for Stratified Medicine, Ulster University, Derry, UK

10.35 - 10.50 Stratified Medicine in Proinflamatory Multi-morbid Disease

**Tony Bjourson** 

Director, Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Derry, UK

10.50 - 11.10 A Gut Feeling about Mental Health: Precision Medicine and the Microbiome

John F. Cryan

Chair, Department of Anatomy and Neuroscience, APC Microbiome Institute, University College Cork, Ireland

11.10 - 11.30 Personalised Medicine approaches to immunological mechanism and treatment for major psychiatric disorders

**Golam Khandaker** 

Wellcome Trust Intermediate Clinical Fellow, Department of Psychiatry, University of Cambridge, UK

11.30 - 12.00 Round Table

12.00-12.10 Proffered Paper Presentation

Ex-vivo drug screening in patients with inflammatory bowel disease

Katie Lloyd

University Of Liverpool, Liverpool, UK



Centre for Experimental Medicine (CEM) Queen's University Belfast Special Session: Eyes do not lie – you are what you can see! Options for personalised medicine in eye diseases

Meeting Room 2
10.30 - 10.35

**Chair: Tunde Peto** 

Centre for Experimental Medicine, Queen's University Belfast, UK

10.35 - 10.45 Curing diabetic eye disease? - from the bench to treating patients as individuals

Alan Stitt

Professor, Centre for Experimental Medicine, Queen's University Belfast, UK

10.45 - 11.00 Precision Ophthalmology: Lessons from age related macular disease

**Carel Hoyng** 

Professor of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands













11.00 11.15	The myopia epidemic: can we individualise the message? Caroline Klaver Professor of Ophthalmology at Erasmus MC & Radboud UMC The Netherlands
11.15 - 11.25	Micronutrients and age related eye disease: from diet through drugs to prevention of blindness Imre Lengyel Centre for Experimental Medicine, Queen's University Belfast, UK
11.25 - 11.40	Pharmacogenetics and the individual patient: the industry perspective Everson Nogoceke Biomarker Experimental Medicine Leader, Roche Pharma Research & Early Development, Roche, Basel, Switzerland
11.40 - 11.55	How to improve imaging technology to accommodate individual needs? Anne-Marie Cairns Global Vice President of Clinical & Medical Affairs, Optos, Halbeath, UK
11.55 - 12.10	Q&A



## ELIXIR - Genomics and Health (GA4GH) Special Session Empowering personalised health through data sharing

Meeting Room 3A	meatti tiii ougii uata sharing
10.30 - 10.35	Chair: Julia Wilson Associate Director, Welcome Trust Sanger Centre, Cambridge, UK; Clinical Working Group, GA4GH
10.35 - 10.45	Enabling global data sharing for genomics Julia Wilson Associate Director, Welcome Trust Sanger Centre, Cambridge, UK; Clinical Working Group, GA4GH
10.45 - 10.55	Towards data sharing for Personalised Medicine Susheel Varma Human Genomics and Translational Data Technical Coordinator, ELIXIR, Cambridge, UK
10.55 - 11.10	EGA - Towards a federated network of nodes hosting human genetic and phenotype data Thomas Keane Team Leader: EGA, EVA and archive infrastructure EMBL-EBI
11.10 - 11.20	Sharing Data Under the General Data Protection Regulation

11.10 - 11.20 Sharing Data Under the General Data Protection Regulation
Sarion Bowers
Policy Lead, Sanger Institute, Cambridge, UK

11.20 - 11.35 The Swiss Personalized Health Network: Building an interoperable data ecosystem for personalized health research
Torsten Schwede

Professor of Bioinformatics, SIB Swiss Institute of Bioinformatics & University of Basel, Switzerland

11.35 - 11.50 Using Human Genetics to make new Medicines

Jeff Barrett

Director, Open Targets, Cambridge, UK

12.00 - 12.10 Proffered Paper Presentation

Q&A

Using polygenic risk scores to determine risk of post-transplant skin cancer Caragh Stapleton

Royal College of Surgeons in Ireland, Dublin, Ireland



11.50 - 12.00

### Converting Hospitals to a Personalised Health Agenda

10.30 - 10.40 Chair: Pascal Garel

Chief Executive, Hospital and Healthcare Federation (HOPE), Brussels, Belgium

10.40 - 10.55 Unique possibilities for realizing the potential of Personalised Medicine in the Danish healthcare system Eva Weinreich-Jensen


President, HOPE & Senior Advisor, Danish Regions, Denmark

10.55 - 11.15 From Carpet Bombing to Sniper Fire: Genomics to Precision Cancer Care in Children and Adolescents
Owen Smith CBE

Professor of Paediatric and Adolescent Medicine, University College Dublin and Director, Clinical Academic Directorate for Cancer Care, Ireland East Hospital Group Ireland













11 15 - 11.30 Integrated Molecular Pathology: The Belfast Mode Manuel Salto-Tellez Professor of Pathology, Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK 11.30 - 11.40 Stephen McMahon Chairman and co-founder of the Irish Patients' Association (IPA), Dublin, Ireland 11.40 - 12.00 **Round Table Discussion** 12.00 - 12.10 **Proffered Paper Presentation** Identification of a molecular subgroup of stage II/III colorectal cancer patients who benefit from adjuvant 5FUbased chemotherapy Wendy Allen

12:10 - 12:50 Hall 1

**Lunch, Posters and Networking** 



#### Presidential Session: Research Frontiers in Personalised Medicine

Co-Chair: Denis Horgan

Executive Director, European Alliance for Personalised Medicine (EAPM) Brussels, Belgium

Co-Chair: James N'Dow

Chariman, Guidelines Office Board, European Association of Urology (EAU), Arnhem, The Netherlands

12.50 - 13.00 Mairead O'Driscoll

Health Research Board of Ireland, Dublin, Ireland and IC-Per Med

13.00 - 13.10 **Peter Keeling** 

Chief Executive Officer, Diaceutics

CCRCB, Queen's University Belfast, UK

13.10 - 13.25 The ACC (Alliance Against Cancer) approach for Personalized Medicine in Cancer at a national level

Scientific Director, IRCCS, Instituto Nazionale Tumori "Regina Elena, Rome, Italy

13.25 - 13.40 A personalized health strategy for Canada: a funders perspective

Stephen M Robbins

Scientific Director, CIHR Institute of Genetics, Montreal, Canada

13.40 - 13.50 Personalised medicine - Actions at EU level

Stéphane Hogan

Head of Sector for Neuroscience, DG Research & Innovation, European Commission, Brussels, Belgium

13.50 - 14.05 Pursuing Precision in Immuno-oncology - Biology, Big Data and Biomarkers

Tom Lillie

Vice President, Head of European Clinical Development MSD, London, UK

14.05 - 14.20

European Head, Cell and Gene Therapy, Novartis, Basel, Switzerland

14.20 - 14.35 **Q&A Discussion** 

14:35 - 15:00 Hall 1

14:35 - 15:00

## Coffee, Posters and Networking

### **Speed Networking (Hall 1)**

**Patient** representative

> Lydia Makaroff Director, ECPC

Meet the

Meet the **Research Expert** 

Mairead O'Driscoll Health Research Board of Ireland, Dublin, Ireland and IC-Per Med

Meet the **Epidemiologist** 

Michel Coleman Professor of

Epidemiology and Vital Statistics, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK Meet the **Scientist** 

**Gennaro Ciliberto** Scientific Director, IRCCS, Instituto Nazionale Tumori "Regina Elena,

Meet the **Cancer Expert** 


Fabien Calvo

Cancer Core Europe, Paris, France: SAP Health - Institute Gustave Roussy

Scientific Director, Rome, Italy













#### Meet the Eyes Expert

**Caroline Klaver** 

Professor of Ophthalmology at Erasmus MC & Radboud UMC, The Netherlands

#### Meet the Urology Expert

**Hendrik Van Poppel** 

European Association of Urology, Leuven, Belgium

## Meet the **Business Leader**

Peter Keeling Chief Executive Officer, Diaceutics

# Meet the Communication Expert

Andy Powrie-Smith Executive Director, Communication and Partnership, EFPIA, Brussels,

Belgium

# Meet the Regulatory Expert

Stephane Lejeune
EU Programme
Coordinator,
European
Organisation for
Research and
Treatment of Cancer

(EORTC), Brussels, Belgium

15:00 - 16:40 Parallel Sessions



## Mini Symposium: Breast Cancer: Dealing with Complexity Head on to Better Personalised Treatment

15:00 - 16:40 The Studio Supported in part by the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT

15.00 - 15.05 Chair: William Gallagher

Director Conway Institute for Biomolecular Research, University College Dublin, Ireland

15.05 - 15.15 The changing face of breast cancer biomarkers

Michael J. Duffy

Adjunct Professor, School of Medicine and Medical Science, UCD, Ireland

15.15 - 15.25 The advent of multi-gene prognostic signatures

Ivana Sestak

Lecturer in Medical Statistics, Wolfson Institute of Preventitive Medicine, Queen Mary University of London, UK

15.25 - 15.40 Familial breast cancer: diagnostic and treatment dilemmas

**Fergus Couch** 

Chair, Division of Experimental Pathology, Mayo Clinic, Rochester, Minnesota, USA

15.40 - 15.50 The wealth of therapeutic options available in breast cancer

**Cathy Kelly** 

Professor, Mater Misericordiae University Hospital, Dublin, Ireland

15.50 - 16.00 The regulatory perspective

Iñaki Gutiérrez-Ibarluzea

Vice President in Health Technology Assessment International (HTAi), Basque Region, Spain

16.00 - 16.10 EU support for first demonstration of value of personalised medicine - the TRANSBIG case study

Stéphane Hogan

Head of Sector for Neuroscience, DG Research & Innovation, European Commission, Brussels, Belgium

16.10 - 16.20 Q&A

16.20 - 16.40 Proffered Paper Presentations

16.20 - 16.30 Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast

Cancer Bo Li

UCD, Dublin, Ireland

16.30 - 16.40 Characterisation of immune infiltrate and STING pathway activation in DNA damage response deficient (DDRD)

breast cancer

**Eileen Parkes** 

CCRCB, Queen's University Belfast, UK



### Genomics and Medicine - Crossing the Rubicon

15.00 - 15.05 Chair: Shane McKee

Director Northern Ireland Genomics Medicine Centre, Belfast, UK

15.05 - 15.20 Johan T den Dunnen

Professor of Medical Genomics, Human & Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands

15.20 - 15.35 Andrew Spiegel

Executive Director, Global Colon Cancer Assocation, Philadelphia, USA













15.35 - 15.50	Individualizing Care for Patients with Multiple Chronic Conditions  Daniel Schneider  Director Diagnostics and Personalised Medicine, Teva Pharmaceuticals, Philadelphia, USA
15.50 - 16.10	Involving the public in conversations about Genomics: making Personalised Medicine resonate Anna Middleton Head of Society and Ethics Research Wellcome Genome Campus, Cambridge, UK
16.10 - 16.30	Round Table Discussion
16.30 - 16.40	Proffered Paper Presentation
	Predicting genetic disease risks in children by whole genome sequencing  M Stephen Meyn  The Hospital For Sick Children, Toronto, Canada



## Realising precious therapeutics in neurological disease

15.00 - 15.15	Chair: Gianpiero Cavalleri Associate Professor in Human Genetics, RCSI, Dublin, Ireland
15.15 - 15.35	Precision molecular diagnostics Slave Petrovski NHMRC Fellow, Royal Melbourne Hospital, University of Melbourne, Australia
15.35 - 15.50	eHealth enabled precision, proactive, personalised care Mary Fitzsimons Medical Physicist, Beaumont Hospital, Dublin, Ireland
15.50 - 16.10	Clinical integration Norman Delanty Professor of Clinical Neurological Sciences, Beaumont Hospital, Dublin, Ireland



16.10 - 16.30

**Round Table** 

# The EU Policy on Lung Cancer screening: It's time to start planning for

15:00 - 16:40 Meeting Room 3A	implementation across Europe
15.00 - 15.10	Chair: John Field Professor of Molecular Oncology, University of Liverpool, UK
15.10 - 15.25	Antoni Montserrat Senior Expert on Cancer and Rare Diseases, DG Public Health, European Commission, Brussels, Belgium
15.25 - 15.40	Gerry Hanna Senior Lecturer and Consultant in Clinical Oncology, CCRCB, Queen's University Belfast, UK
15.40 - 15.55	Sebastian Schmit Professor of Neuroradiology and Head/Neck Radiology, Erasmus MC, Rotterdam, The Netherlands
15.55 - 16.05	EU position statement on lungcancer screening Matthijs Oudkerk Scientific Director Centre for Medical Imaging, North East, Netherlands

16.05 - 16.15 Lung Cancer Screening - is Europe heading in the right direction? **Anne Marie Baird** LUCE representative & Senior Research Follow, St. James's Hospital, Dublin, Ireland

16.15 - 16.40 **Round Table Discussion** 
















## The most dreadful "neglected" cancer: pancreatic cancer

15.05 - 15.25	Personalized genomics medicine Andrew Biankin Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow, UK
15.25 - 15.40	The patient's perspective Ali Stunt Founder of Pancreatic Cancer Action, Oakhanger, UK
15.40 - 15.50	The Family's and society's perspective Lydia Makaroff Director, European Cancer Patient Coalition (ECPC), Brussels, Belgium
15.50 - 16.00	Diagnostic challenges Matthias Lohr Professor of Gastroenterology & Hepatology, Centre of Biosciences, Karolinksa Institutet, Stockholm, Sweden
16.00 - 16.10	Pancreatic cancer treatment progresses Alfredo Carrato Professor of Medical Oncology, Institution Ramon y Cajal University Hospital, Madrid, Spain
16.10 - 16.25	Research gaps and needs Nuria Malats Group Leader, Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Madrid, S

16.40 - 17.15 Auditorium	Special Lecture "Keep the person in personalised healthcare"  Gretchen Rubin, Author and Podcaster, New York, USA	
17:15 - 17:30 Hall 1	Coffee, Posters and Networking	
17:30 - 19:00	Parallel Sessions	



16.25 - 16.40

Q&A

### Cancer in Europe: Responding to the Challenge

17.30 - 17.40	Chair:	Richard	Sullivan
17.30 17.40	Cilaii.	Nichala	Juliivali

Director, Institute of Cancer Policy, King's College London UK

#### 17.40 - 17.55 Cancer in Eastern Europe - a Call for Action

Mark Lawler

Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK

#### 17.55 - 18.05 Marius Gaenta

Co-Founder, Center for Innovation in Medicine, Bucharest, Romania

#### 18.05 - 18.15 Jasmina Koeva-Balabanova

Chair of the Board, Bulgarian Alliance for Personalised Medicine - BAPPM, Sofia, Bulgaria

#### 18.15 - 18.30 Florin Buicu

President Health Commission, Chamber of Deputies, Romanian Parliament, Bucharest, Romania

### 18.30 - 18.45 The primary tasks and responsibilities of personalized medicine in Poland


Beata Jagielska

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Department of Oncological Diagnostic, Cardio-Oncology and Palliative Care, Warsaw, Poland

18.45 - 19.00 Round Table Discussion















## Big data in hematology; accelerating more efficient drug development, regulatory evaluation, access appraisal and treatment strategies (HARMONY)

17:30 - 17:35 Word of welcome on behalf of the Harmony Association

**Carin Smand** 

Managing Director, European Hematology Association, The Hague, The Netherlands

Patricia van Dijck

Director Healthcare Systems Solutions Novartis Oncology Region Europe, Novartis

17:35 - 18:05 Keynote Lecture: Better health care with big dating

Egge van der Poel

Clinical Data Scientist Erasmus University Medical Centre, Rotterdam, The Netherlands

18:05 - 18:15 Enabling Better and Faster Treatment for Patients with Hematologic Malignancies

**Carin Smand** 

Managing Director European Hematology Association

Patricia van Dijck

Director Healthcare Systems Solutions Novartis Oncology Region Europe, Novartis

18.15 - 19.00 Debate: How to apply Big Data in patient care, regulatory systems and drug approval processes? Big data &

Hematology: what are the specifics we need to take into account?

**Moderators:** 

Patricia van Dijck & Carin Smand

Tamás Bereczky

Country Coordinator EUPATI Germany National Platform, Communications Officer of EUPATI EU, Berlin, Germany

Pam Bacon

Executive Director Medical Affairs, Celgene

Dr. Guillermo F. Sanz Santillana

Head of Clinical Hematology Section, Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana (HULAFE), Valencia, Spain

Dr Egge van der Poel

Clinical Data Scientist, Erasmus University Medical Center, Rotterdam, The Netherlands



## Clinical Innovation Showcase: 'Northern Ireland Clinical Research Network(NICRN) : supporting clinical research in personalised medicine'

Co-Chairs: Paul Biagioni, Maurice O'Kane

NICRN

17.30 - 17.40 Introduction

Maurice O'Kane

**NICRN** 

17.40 - 17.55 Cardiovascular Disease

Patrick Donnelly

Co-clinical Lead of the Northern Ireland Cardiovascular Research Network, South Eastern Health and Social Care

Trust. UK

17.55 - 18.10 Looking at personalised medicine through a different lens

**Vivien Coates** 

Professor of Nursing Research, Ulster University, Coleraine, UK

18.10 - 18.40 Renal Medicine Research - from GENIE to GFR

Peter Maxwell

Professor of Renal Medicine, Queen's University Belfast, UK

Neal Morgan

Consultant Nephrologist, Newry, UK

18.40 - 18.50 Q&A

18.50 - 19.00


**Proffered Paper Presentation** 

Multivariate analysis enables personalized prediction of adverse heart and kidney outcomes

Tel Aviv University, Tel Aviv, Israel

















## Systems Medicine, big data and scientific wellness: transforming healthcare – a proteomics perspective

Professor of Proteomics, President Elect HUPO, Conway Institute for Biomolecualr Research, UCD, Ireland

Where and how proteomics can deliver: integration of proteomics data with other 'omics data towards integrated diagnostics

Alain van Gool

Professor Personalized Healthcare, Head Translational Metabolic Laboratory, Chair EATRIS Biomarker Platform, Radboud university medical center, Nijmegen, The Netherlands

17.45 - 17.55 From population to person: protein biomarkers for personalised healthcare

Albert Sickmann
President, ISAS e.V., Dortmund, Germany

Chair: Prof Stephen R Pennington

Liquid biopsy - impact on personalised healthcare - longitudinal monitoring

**Chris Sutton** 

Institute of Cancer Therapeutics, University of Bradford, UK

18.05 - 18.15 Delivery of proteomics to healthcare systems

Andrea Urbani

President European Proteomics Association (EuPA), Chair of Biochemistry, Catholic University of the "Sacred Heart", Rome. Italy

18.15 - 18.30 Discovery proteomics in action

**Tony Whetton** 

Director of the Stoller Biomarker Discovery Centre and Manchester Precision Medicine Institute, University of

Manchester, UK

18.30 - 18.50 Q&A

**Proferred Paper Presentation** 

Tackling acquired resistance mechanisms in malignant melanoma

**Jens Rauch** 

UCD, Dublin, Ireland



18.50 - 19.00

#### Personalised Health and rare disease

17.30 - 17.35 Co-Chair: Alastair Kent

Chair Rare Disease UK; Ambassador, Genetic Alliance, London, UK

Co-Chair: Denis Horgan

Executive Director European Alliance for Personalised Medicine, (EAPM), Brussels, Belgium

17.35 - 17.55 Kim Stratton

Head International Commercial, Shire, London, UK

17.55 - 18.15 Antoni Montserrat

Senior Expert on Cancer and Rare Diseases, DG Public Health, European Commission, Brussels, Belgium

18.15 - 18.30 Clinical trial simulation platform with personalised medicine in mind

Aiden Flynn

CEO, Exploristics Ltd, Belfast, UK

18.30 18.45 CAR T Cell Therapy for Head and Neck Cancer

Sophie Papa

King's College London and Guy's and Thomas' NHS Foundation Trust, London, UK

18.45 - 19.00 Q&A

	Patrick Johnston Memorial Lecture
19:00 - 20:00 Auditorium	Progress and challenges in personalised cancer medicine: Drugs, chemical probes and biomarkers Paul Workman, Chief Executive and President, The Institute of Cancer Research (ICR) UK
	Introduced by Gordon McVie, Co-Chair, EAPM, Brussels, Belgium
	Gala Dinner - Titanic Belfast
20:30 - 22:30	HI-5 Awards
	The Evolving Four Corners of a Personalised Medicine Vista
	Judge Fidelma Macken SC Former judge of the Supreme Court of Ireland and a former judge of the European Court of Justice, Dublin, Ireland











## Wednesday 29 November 2017

08:00 - Audito	

## 30

#### Presidential Session: Is precision medicine the route to a healthy world?

	08.00 - 08.05	Chair: Denis Horgan
--	---------------	---------------------

Executive Director, European Alliance for Personalised Medicine (EAPM) Brussels, Belgium

08.05 - 08.15

Past President, European Brain Council, London, UK

08.15 - 08.25 James N'Dow

Chariman, Guidelines Office Board, European Association of Urology (EAU), Arnhem, The Netherlands

08.25 - 08.40 Francesco De Lorenzo

President, European Cancer Patient Coalition, Brussels, Belgium

08.40 - 08.55 **Michel Coleman** 

Professor of Epidemiology and Vital Statistics, Department of Non-Communicable Disease Epidemiology, London

School of Hygiene and Tropical Medicine, London, UK

08.55 - 09.10 **Fabien Calvo** 

Scientific Director, Cancer Core Europe, Institute Gustave Roussy, Paris, France

09.10 - 09.20 Access to innovation is our joint responsibility

Eelko den Breejen

International Health Policy Leader, Personalised Healthcare, Roche

09.20 - 09.30

09:30 - 10:00 Hall 1	Coffee, Posters and Networking
09:30 - 10:00	Press Briefing Centre (The Studio)
10:00 - 11:30	Parallel Sessions



### Personal Oncology Approaches - reflections from both sides of the pond

**The Studio** 10.00 - 10.10

Co-Chair: Etienne Richer

Associate Director, CIHR Institute of Genetics, Montreal, Canada

Co-Chair: Fabien Calvo

Scientific Director, Cancer Core Europe, Institute Gustave Roussy, Paris, France

10.10 - 10.20 Biomarkers for Pediatric Glioblastoma through Genomics and Epigenomics

Nada Jabado

Associate Professor of Pediatrics, McGill University Health Centre, Montreal, Canada

10.20 - 10.30 Personalized Cancer Immunotherapy

**Denis Claude Rov** 

Director Cellular Therapy Laboratory, Scientific Director, Centre de recherche, Hospital Maisonneuve-Rosemont,

Montreal, Canada

10.30 - 10.40 Personalized Oncogenomics (POG), The BC Cancer Agency's Personalized Oncogenomics Program

Janessa Laskin

Senior Scientist, Medical Oncologist, BC Cancer Agency, Vancouver, Canada

10.40 - 10.50 Ian Walker

Commercial Leader - Region Europe, Roche Foundation Medicine, Basel, Switzerland

10.50 - 11.00 Cancer Core Europe Basket of Basket Clinical trial

Associate Investigator, Vall D'Hebron Institute of Oncology, Barcelona, Spain

11.00 - 11.10 European Pediatric Precision Cancer Medicine Program


**Birgit Georger** 

Head of the Pediatric New Drug Development Program, Gustave Roussy Cancer Campus, Villejuif, France














#### 11.10 - 11.20 A putative role for interleukin 1 pathway in resistance to EGFR blockade

Mattia Lauriola

University Of Bologna, Italy

#### 11.20 - 11.30 Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Oesophageal and

Gastric Adenocarcinoma Richard Turkington

Queens University Belfast, Belfast, UK



## Left behind and burnt out? The lived experience of 'molecularly unstratified' patients and stratified medicine researchers.

Chair: Lisa Wilde

Director of Research and External Affairs, Bowel Cancer UK

#### 10.00 - 10.10 Personalised medicine: for the many or the few?

Tim Maughan

Professor of Clinical Oncology, University of Oxford; MRC/CRUK Stratification in Colorectal Cancer Consortium

### 10.10 - 10.20 A costly promise: Ethical imperatives for 'personalised' medicine

Joshua Hordern

Associate Professor of Christian Ethics, University of Oxford; Oxford Healthcare Values Partnership, University of Oxford

#### 10.20 - 10.30 Richard Sullivan

Chair in Cancer Policy and Global Health, Kings College London

#### 10.30 - 10.40 Alison Hall

Head of Humanities, PHG Foundation, Cambridge, UK

#### 10.40 - 10.45 Burnt out? The stratified trial as a working environment

Liz Morrell

Postdoctoral researcher, Centre for the Advancement of Sustainable Medical Innovation (CASMI), Radcliffe Department of Medicine, University of Oxford, UK

#### 10.45 - 10.55 Psychosocial and behavioural considerations: putting the person into personalised medicine

**Rob Horne** 

Professor of Behavioural Medicine, UCL School of Pharmacy; Centre for the Advancement of Sustainable Medical Innovation, London, UK

#### 10.55 - 11.05 Stratification: Hope or false dawn

Alastair Kent

Chair Rare Disease UK; Ambassador, Genetic Alliance UK

#### 11.05 - 11.30 Round Table Discussions



#### Regulatory Environment for Diagnostics necessary for precision medicine

#### 10.00 - 10.10 Co-Chair: Jonathan Truelove

Vice President, General Counsel International Genomic Health, Geneva, Switzerland

#### 10.10 - 10.20 Frederique Nowak

Head of the Department of Biology, Transfer and Innovations, Research and Innovation Directorate, Institut National du Cancer (INCa), France

#### 10.20 - 10.35 Laura Knoke

Associate Disputes, Environment, planning and regulatory, Freshfields Brockhaus Deringer, Berlin, Germany

#### 10.35 - 10.50 Stephen Lee

Biosciences Team Manager, Medicines and Healthcare products Regulatory Agency, London, UK

#### 10.50 - 11.05 Stanimir Hasurdjiev

Secretary-General of the Patient Access Partnership, Brussels, Belgium

#### 11.05 - 11.15 Armin Ritzhaupt

Science and Innovation Support Office, Product Development Scientific Support Department, European Medicines Agency

11.15 - 11.30 Q&A















## Discover What's Possible – The opportunities and challenges of all-island cancer clinical trial collaboration

10.00 - 10.10 Welcome and Introductions

Co-Chair: Professor Richard Wilson

NICTN Clinical Lead

**Co-Chair: Professor Bryan Hennessy** 

Cancer Trials Ireland Clinical Lead

10.10 - 10.25 A patient's perspective

**Margaret Grayson** 

Chair, NI Cancer Research Consumer Forum, UK

10.25 - 10.40 A techie's guide to cancer trial interoperability for non techies

Austin Tanney
Analytics Engines

10.40 - 10.55 A current look at future possibilities from a policy maker

Sean Donaghy

Director of eHealth and External Collaboration, HSC, UK

10.55 - 11.10 The Interdisciplinary cancer researcher's toolkit

**Niamh Buckley** 

Queens University Belfast, Belfast, UK

11.10 - 11.20 A world class collaborative research funding model

**Rosemary Hamilton** 

Co-chair US Ireland R&D Partnership

11.20 - 11.30 Panel Q&A



### Preserving Health - what can we do at European Level?

10.00 - 10.05 Chair:

Chair: Tit Albreht Institute of Public Health, Slovenia

10.05 - 10.30

**Tit Albreht** 

Institute of Public Health, Slovenia

10.30 - 10.50

Population screening and personalized medicine - a contradiction?

**Sebastian Schmidt** 

Head of Strategy and Medical Affairs Computed Tomography at Siemens Healthineers

10.50 - 11.10

Public health genomics

Marc Van den Bulcke

Head Cancer Centre, OD Public Health and Surveillance Scientific Institute of Public Health, Belgium

11.10 - 11.30

Q&A

#### 11:30 - 12:00 Hall 1

#### **Networking and Poster Viewing**



## Presidential Session: Leaders and Innovators Forum; An Athena Swan Initiative

**Auditorium** 12.00 - 12.10

Chair: Gordon McVie

Co-Chair, EAPM, Brussels, Belgium

12.10 - 12.25

Karen McCloskey

Professor, Centre for Cancer Research and Cell Biology, Institute for Health Sciences, Queens University Belfast, UK

12.25 - 12.40

**Christine Chomienne** 

Director of Research & Innovation, INCa, France

12.40 - 12.55

Françoise Meunier

Director of Special Projects, European Association for the Research and Treatment of Cancer, Brussels, Belgium, Vice-President, Federation of European Academies of Medicine, Brussels, Belgium

12.55 - 13.15 Q&A Discussion













#### Systems Medicine and Personalised Health

The Studio 14.10 - 14.15

Chair: Giovanni Codacci Pisanelli

Assistant Professor in Medical Oncology, University of Rome "La Sapienza", Rome, Italy

14.15 - 14.30 Nuria Malats

Group Leader, Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre

14.30 - 14.45 Precision oncology based on computational modelling

**Walter Kolch** 

Director, Systems Biology Ireland, UCD, Ireland

14.45 - 15.55 Targeting Apoptosis Dependencies in Cancer

**Dan Longley** 

Chair of Cancer Biology, Queens University Belfast, UK

Director, Centre for Systems Medicine, RCSI, Dublin, Ireland

15.05 - 15.15 Clinical utility of precision médicine in oncology

Christophe Le Tourneau

Senior medical oncologist, Institut Curie and Professor of Medicine, Versailles-Saint-Quentin-en-Yvelines University

15.15 - 15.30 Q&A

15.30 - 15.40 Proffered Paper Presentation

Overcoming Intratumoural Heterogeneity For Reproducible Molecular Risk Stratification: A Case Study In

Advanced Kidney Cancer

Ian Overton

CCRCB, Queen's University Belfast, UK



#### Personalised Medicine and Public Health: Two Sides of the Same Coin?

•

14.10 - 14.25

Chair: Walter Ricciardi

Instituto Superiore di Sanità Italy

14.25 - 14.35 Derick Mitchell

Chief Executive, Irish Platform for Patient Organisations, Science & Industry (IPPOSI), Dublin, Ireland

14.35 - 14.50 Frank Kee

Director, UKCRC Centre for Excellence for Public Health Research (NI), Queen's University Belfast, UK

14.50 - 15.00 Kaisa Immonen

Director of Policy, European Patient Forum

15.00 - 15.15 Personalised Medicine - Mind the Gender Gap

**Peggy Maguire** 

Former President, EPHA; Director General, European Institute of Women's Health

15.15 - 15.30 Jerome Foucauc


Responsible Department of Human Sciences, Epidemiology and Public Health, Institut National du Cancer (INCa),

France

15.30 - 15.40 Q&A
















## Fixing Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): Targeting therapies which make a difference

14.10 - 14.15 Co-Chair: J Stuart Elborn

Imperial College and Royal Brompton Hospital, London and Queen's University Belfast, UK

Co-Chair: Lorraine Martin

Professor of Molecular Pharmaceutics, School of Pharmacy, Queen's University Belfast, UK

14.15 - 14.30 How the Cystic Fibrosis Transmembrane Regulator (CFTR) works

**Lorraine Martin** 

Professor of Molecular Pharmaceutics, School of Pharmacy, Queen's University Belfast, UK

14.30 - 14.45 Modulating the Cystic Fibrosis Transmembrane Regulator (CFTR): How New Drugs were developed

Mark Higgins

Vertex Pharmaceuticals Europe, London, UK

14.45 - 15.00 Treating Cystic Fibrosis: New Clinical Trials

J Stuart Elborn

Imperial College and Royal Brompton Hospital, London and Queen's University Belfast, UK

15.00 - 15.10 Living with Cystic Fibrosis

Michelle Francis Naylor

Consultant Psychiatrist, Belfast, UK

15.10 - 15.20 Future Challenges, Policy and Science

Janet Allen

Director of Strategic Innovation, Cystic Fibrosis Trust, Southampton, UK

15.20 - 15.40 Round Table Discussion



**3A** 

### Health Literacy: A Key Component of Personalised Health and Innovation

14.10 - 14.15 Chair: Denis Horgan

European Alliance for Personalised Medicine, Brussels, Belgium

14.15 - 14.30 Holger Moch

Medical Director and Chairman, Department of Pathology & Molecular Pathology, University Hospital Zurich, Switzerland

14.30 - 14.40 Stephen McMahon

Chairman and co-founder of the Irish Patients' Association (IPA)

14.40 - 14.55 Kristine Sørensen

Founder, Global Health Literacy Academy, Urmond, The Netherlands

14.55 - 15.05 Geoffrey Henning

Policy Director, EuropaColon, Brussels, Belgium

15.05 - 15.20 Andy Powrie-Smith

Executive Director, Communication and Partnership, EFPIA, Brussels, Belgium

15.20 - 15.30 Q&A

15.30 - 15.40 Proffered Paper Presentation

Exploring information and communication to help empower individuals affected by rare disease(s) in Northern Ireland

Jane Miller

Centre for Public Health? Queen's University Belfast, UK



**Meeting Room** 

#### Genomics, DNA and Diaspora

14.10 - 14.15 Co-Chair: Eimear Kenny

Assistant Professor, Icahn School of Medicine at Mount Sinai, NY, USA

14.15 - 14.20 Co-Chair: Joe McHugh TD

Minister of State for the Diaspora and International Development













14.20 - 14.35	John Greally Professor, Faculty Scholar for Epigenetics, Albert Einstein College of Medicine, New York, USA
14.35 - 14.50	Dan Bradley Principal Investigator, molecular Population Genetics, Smurfit Institute of Genetics, Trinity College Dublin, Ireland
14.50 - 15.05	Eimear Kenny Assistant Professor, Icahn School of Medicine at Mount Sinai, NY. USA
15.05 - 15.20	<b>Tõnu Esko</b> Deputy Director of Research, Estonian Biobank, Estonian Genome Center, University of Tartu, Estonia
15.20 - 15.40	Round Table Discussion

15:40 - 16:10 Hall 1

#### Coffee, Posters and Networking

#### **Speed Networking (Hall 1)**

Meet the Public Health Expert	Meet the Pancreatic Expert	Meet the Health Literacy Expert	Meet the Pathologist	Meet Patient Representative
Walter Ricciardi Instituto Superiore di Sanità Italy	Nuria Malats Group Leader, Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre	Kristine Sørensen Founder, Global Health Literacy Academy, The Netherlands	Holger Moch Medical Director and Chairman, Department of Pathology & Molecular Pathology, University Hospital Zurich, Switzerland	Geoffrey Henning Policy Director, EuropaColon, Brussels, Belgium
Meet the Oncologist  Beata Jagielska Maria Sklodowska- Curie Memorial Cancer Center and Institute of Oncology; Department of Oncological Diagnostic, Cardio- Oncology and Palliative Care,	Meet the Regional Expert  Marius Gaenta Co-Founder, Center for Innovation in Medicine, Bucharest, Romania	Meet the Business Leader Tom Lillie Vice President, Head of European Clinical Development MSD, London, UK	Meet the Biochemistry Expert  Mario Pazzagli Professor of Clinical Biochemistry, Department of Clinical and Experimental Biochemical Science, University of Florence, Italy	Meet the Regulatory Expert  Jonathan Truelove Vice President, General Counsel International Genomic Health, Geneva, Switzerland



## Shooting for the Moon or Flying too near the Sun: Crossing the Value Rubicon in Precision Care

16.10 - 16.15 Co-Chair: Mark Lawler

Chair in Translational Cancer Genomics, Queen's University Belfast, UK

16.15 - 16.20 Co-Chair: Richard Sullivan

Director, Institute of Cancer Policy, King's College London UK

16.20 - 16.35 Richard Sullivan

Director, Institute of Cancer Policy, King's College London UK

16.35 - 16.55 Tito Fojo

Professor of Medicine, Columbia University, New York, USA

16.55 - 17.10 Mark Lawler

Chair in Translational Cancer Genomics, Queen's University Belfast, UK

17.10 - 17.25 Virginia Acha

Executive Director, EU, EMEA, APAC Regulatory Policy, MSD, London, UK

17.25 - 17.40 Q&A

17:40 - 18.45	Poster Session
19.00 - 20.30	Irish Experience and Special Performance













## **Thursday 30 November 2017**



## **Auditorium**

#### Presidential Session: Personalised Medicine Through Open Innovation

08.00 - 08.10 **Chair: Pierre Meulien** 

Innovation Medicines Initiative (IMI) Brussels, Belgium

08.10 - 08.30 **U-BIOPRED Project - Peter Sterk** 

> Professor, Department of Respiratory Medicine in the Academic Medical Centre (AMC) of the University of Amsterdam, Amsterdam, The Netherlands

08.30 - 08.50 **EU - AIMS Project - Declan Murphy** 

Professor, Kings College London

08.50 - 09.10 **CANCER - ID Project - Barbara Baggiani** 

Chief Marketing Officer, Silicon Biosystems - A Menarini Group Company, Florence, Italy

09.10 - 09.30 **Round Table Discussion** 

09:30 - 10:00 Hall 1	Coffee, Posters and Networking
09:30 - 10:00	Press Briefing Centre (The Studio)
10:00 - 11:40	Parallel Sessions



### The Challenges of Precision Oncology Drug Development and Implementation

The Studio 10.00 - 10.05

Co-Chair: Andrew Biankin

Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow

Co-Chair: Simon J Hollingsworth

Executive Director, AstraZeneca, Oncology IMED Biotech Unit

10.05 - 10.25 Challenges of Contemporary Therapeutic Development

Simon J Hollingsworth

Executive Director, AstraZeneca, Oncology IMED Biotech Unit

Diversity and Defining Actionability of Molecular Events 10.25 - 10.45

Precision oncology, cancer genomics and next-generation therapeutics - Sanger Institute, Cambridge, UK

10.45 - 11.05 Effective Strategies for approval

**Shirley Hopper** 

MHRA

11.05 - 11.25 Composite Datasets and Knowledge Banks

**Andrew Biankin** 

Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow, UK

11.25 - 11.40 Q&A



#### Connected Health - Defining the Vision and Business in a Changing Environment

10.00 - 10.05

Chair:Brian O'Connor

Chair, European Connected Health Alliance, Belfast, UK

10.05 - 10.25

**Brian O'Connor** 

Chair, European Connected Health Alliance, Belfast, UK

10.25 - 10.45

Jim McLaughlin OBE

University of Ulster, Antrim, UK













10.45 - 11.00	Optimising medicines for patients Mike Scott Medicines Optimisation Innovation Centre, Antrim, UK
11.00 - 11.20	George Crooks OBE CEO, Digital Health &Care Institute, Glasgow, UK
11.20 - 11.40	Q&A



#### We are what we eat - preserving health through enhanced nutrition

10.00 - 10.05 Chair: Christopher Elliott

Chair of Food Safety & Microbiology, Pro Vice Chancellor Faculty of Medicine, Health and Life Sciences, Queen's

University Belfast, UK

10.05 - 10.30 From the French Revolution to the Food Revolution

**Christopher Elliott** 

Chair of Food Safety & Microbiology, Pro Vice Chancellor Faculty of Medicine, Health and Life Sciences, Queen's

University Belfast, UK

10.30 - 10.50 Delivering a breakthrough in human nutrition and health through delivery of omega oils in chicken meat

**Alice Stanton** 

Royal College of Surgeons in Ireland, Dublin, Ireland

10.50 - 11.10 The world's first nexus city for food, education, trust and health - Project Daire

**Moira Deane** 

Institute for Global Food Security, Queen's University Belfast, UK

11.10 - 11.20 Q&A

11.20 - 11.40

**Proffered Paper Presentations** 

11.20 -11.30 An RCT investigating ABPM response to riboflavin in adults with a common folate polymorphism: a personalised

approach to managing BP

Catherine F Hughes

Ulster University, Londonderry, UK

11.30 - 11.40 Alterations to offspring DNA methylation levels in response to maternal folic acid supplementation during second

and third trimester of pregnancy

Sara-Jayne Thursby

Ulster University, Belfast, UK



**3A** 

#### Precision Pathology in LMICs - unaffordable luxury or relevant necessity?

10.00 - 10.05 Chair: Kenneth Fleming

Senior Advisor for Pathology, Centre for Global Health NCI, Washington

10.05 - 10.25 Precision pathology in low- and middle-income countries: challenges and opportunities

**Richard Sullivan** 

Director, Institute of Cancer Policy, King's College London UK

10.25 - 10.45 The current status of Pathology in low- and middle-income countries

**Kenneth Fleming** 

Senior Advisor for Pathology, Centre for Global Health NCI, Washington

10.45 - 11.05 Can low- and middle- income countries afford precision pathology?

Sue Horton

Professor and GICI Chair in Global Health Economics, University of Waterloo, Canada


11.05 - 11.25 Precision pathology and Point-of-Care Testing in LMICs: Look before you Leapfrog

Mark Lawler

Chair in Translational Cancer Genomics, Queen's University Belfast, UK


11.25 - 11.40 Round Table Discussion













## 10:00 - 11:40 **Meeting Room**

#### HTA, Payers & the European Medicines Agency – Crossing the Rubicon

10.00 - 10.10 Chair: Denis Horgan

European Allaince for Personalised Medicine, Brussels, Belgium

10.10 - 10.35 Value Frameworks and Personalised Medicine: The Need for Augmented Cost-Effectiveness Analysis

Lou Garrison

Past President, International Society For Pharmacoeconomics and Outcomes Research, Washington DC, USA

10.35 - 10.55 Clare Haque

Director of Health Economics & Outcomes Research Medical Affairs, Celgene, Boudry, Switzerland

10.55 - 11.15 **Carole Longson** 

Director, Centre for Health Technology Evaluation and Executive Director, National Institute for Health Care &

Excellence (NICE), London, UK

11.15 - 11.25 Giovanni Codacci Pisanelli

Assistant Professor in Medical Oncology, University of Rome "La Sapienza", Rome, Italy

11.25 - 11.40 **Round Table Discussion** 

11:40 - 12:00 Hall 1

#### **Coffee, Posters and Networking**



#### 12:00 - 13:40 **Auditorium**

Presidential Session: Regulating the future - Balance of patient safety and facilitating Innovation (EMA - FDA)

12:00 - 12:05 Chair: Denis Horgan

Executive Director, European Alliance for Personalised Medicine

12.05 - 12.15

Chair European Alliance for Personalised Medicine, Brussels, Belgium

12.15 - 12.30 Recommendation of the ISPOR Special Task Force on U.S. Value Assessment Frameworks

Lou Garrison

Past President, International Society For Pharmacoeconomics and Outcomes Research, Washington DC, US

12.30 - 12.45 Juergen Scheuenpflug

Global Head Clinical Biomarkers & Companion Diagnostics, MSD

12.45 - 13.00

Director, Population Genomics Illumina, Inc., London, UK

13.00 - 13.15 Iñaki Gutiérrez-Ibarluzea

Vice President en Health Technology Assessment international (HTAi), Basque Region Spain

13.15 - 13.30 Personalised Medicine, Regulating the future

**Brian Aylward** 

Health Products Regulatory Authority, Dublin, Ireland

13:30 - 13:40 **Q&A Discussion** 

13:40 - 14.20

#### **Lunch, Posters and Networking**

### **Speed Networking (Hall 1)**

## Hall 1

## **Meet the HTA Expert**

Iñaki Gutiérrez-Ibarluzea Vice President en Health Technology

Assessment international (HTAi). Basque Region Spain

#### Meet the **Economist**

## **Lou Garrison**

Past President. International Society For Pharmacoeconomics and Outcomes Research, Washington

DC, US

#### Meet the **Pathologist**

#### Kenneth Fleming. Senior Adviser for

Pathology, Centre for Global Health NCI. Washington

#### **Meet the Industry** Representative

#### Eelko den Breejen

International Health Policy Leader, Personalised Healthcare, Roche


#### **Meet the Patient** Representative

#### **Peter Kapitein**

Inspire2Live. The Netherlands













#### Meet the Regional Expert

#### Jasmina Koeva-Balabanova

Chair of the Board, Bulgarian Alliance for Personalised Medicine - BAPPM, Sofia, Bulgaria

# Meet the Pancreatic Expert

#### **Andrew Biankin**

Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow, UK

#### Meet the Health Economics Expert

# Clare Hague EMEA Glo Director of Health Economics &

Mario Romao EMEA Global Public Policy team, Intel

**Meet the Data** 

**Expert** 

# Meet the Innovation Expert

Pierre Meulien Innovation Medicines Initiative (IMI) Brussels, Belgium

14.20 - 16:00

#### **Parallel Sessions**

Outcomes Research

Medical Affairs,

Celgene, Boudrv.

Switzerland



## **EAU Special Session Every Prostate cancer is unique: Personalised prostate cancer diagnosis and management**

14.20 - 14.30 Chair: Hendrik Van Poppel

European Association of Urology, Leuven, Belgium

14.30 - 14.45 Nicolas Mottet

Urology Department Head at CHU St Etienne - Université Jean Monnet, St Etienne, France

14.45 - 15.00 Rodolfo Montironi

Chairman, EAU Section of Uropathology (ESUP), Ancona, Italy

15.00 - 15.15 Thorsten Bach

Chairman EAU Patient Information Projekt, European Association of Urology, Munich, Germany

15.15 - 15.30 Ian Banks

President, European Men's Health Forum, Brussels, Belgium

15.30 - 15.40 Q&A

15.40 - 16.00 Proffered Paper Presentation

15.40 - 15.50 Enhanced radio-sensitivity of PTEN-deficient prostate tumours mediated by inhibition of intrinsic and treatment-

potentiated CXC-chemokine signalling

Chris Armstrona

CCRCB, Queen's University Belfast, UK

Combined DNA repair inhibition and radiotherapy strategies targeting the PTEN axis in prostate cancer

Karl Butterworth

Queen's University Belfast, UK



## The Value of Innovation from the Cancer Patient Perspective

14.20 - 14.25

Chair: Lydia Makaroff

Director, ECPC, Brussels, Belgium

14.25 - 14.40

The Value of Innovation from the Cancer Patient Perspective

Lydia Makaroff

Director, ECPC, Brussels, Belgium

14.40 - 14.55

Access to Immuno-Oncology and other Innovations for People with Cancer in the United Kingdom

**Constantinos Chrysaphinis** 

Patient Involvement and Projects Officer, the Brain Tumour Charity, UK

14.55 - 15.15

Current and Developing Innovation in Colorectal Cancer

Stephen Halloran

Public Health England and University of Surrey, Surrey, UK

15.15 - 15.30

Addressing the Europe of Disparities in Cancer

Mark Lawler

Queen's University Belfast, UK

15.30- 15.45

The Cancer Innovation Challenge

Dave Fitch

Head of Operations, The Data Lab, Aberdeen, UK

15.45 - 16.00 Panel Discussion with key stakeholders
















#### **Diabetes: A Personalised Health Epidemic**

14.20 - 14.25	Co-Chair: Olivier Arnaud
	Senior Director, Juvenile Diabetes Research Foundation, Paris, France

Co-Chair: Jeannette Soderberg

Senior Director Research Europe, JDRF, USA / European Project Manager, JDRF, USA

14.25 - 14.45 Staging Type 1 Diabetes and its Prevention through Innovative Interventions

Ake Lernmark

LU Diabetes Centre, Lund University, Sweden

14.45 - 15.05 Pediatric vs Adult onset Type 1 Diabetes - Clinical Considerations in Therapy Development

Colin Dayan

Professor of Clinical Diabetes and Metabolism, Cardiff University, UK

15.05 - 15.25 Accelerating Therapy Development for Diabetic Nephropathy

**Kumar Sharma** 

Chief of Nephrology, Vice Chair of Research, UT Health, USA

15.25 - 15.45 Automated closed loop approaches to personalized medicine

Sanjoy Dutta

15.45 - 16.00 Round Table Discussion / Panel Discussion Q&A



### Molecular Diagnostics - Enabling the Personalised Medicine Revolution

14.20 - 14.30 Co-Chair: David Barton

National Centre for Medicial Genetics, Dublin, Ireland

14.30 - 14.40 Co-Chair: Mario Pazzagli

Professor of Clinical Biochemistry, Department of Clinical and Experimental Biochemical Science, University of

Florence, Italy

14.40 - 15.00 The new IVD regulation

**David Barton** 

Chief Scientist, National Centre for Medical Genetics, Dublin, Ireland

15.00 - 15.20 A Workflow for molecular diagnostics in clinical oncology

Mario Pazzagli

Professor of Clinical Biochemistry, Department of Clinical and Experimental Biochemical Science University of Florence, Italy

15.20 - 15.35 Flushing out the truth! Development of a multiplex urinary tract infection detection test

**Martin Crockard** 

Molecular Diagnostics Manager, Randox Laboratories Ltd, Antrim, UK

15.35 - 15.50 Precision medicine in South Asia: Challenges and Opportunities

**Vidam Ramprasad** 

Chief Operating Officer, MedGenome, Bengaluru, India

15.50 - 16.00 Q&A















## CCRCB – ALMAC Session – The Realities of Delivering Personalised Medicine in Clinical Trials

14.20 - 14.30 Chair: Richard Kennedy

McClay Professor in Medical Oncology, Queen's University Belfast and Global VP of Biomarker Development, Almac Diagnostics, Craigavon, UK

14.30 - 14.50 A Past and Present look at Clinical Trials & Drug Development

Darren Hodgson

Senior Principal Translational Scientist, AstraZeneca, Stcckport, UK

14.50 - 15.15 The Future Landscape of Personalised Medicine

**Matt Squires** 

Executive Director Oncology Precision Medicine Novartis, Basel, Switzerland

15.15 - 15.35 The Changing Regulatory Framework for Personalised Medicine

**Stewart McWilliams** 

VP of Quality & Regulatory, Almac Diagnostics, Craigavon, UK

15.35 - 15.50 Q&A and Wrap Up

**Richard Kennedy** 

McClay Professor in Medical Oncology, Queen's University Belfast and Global VP of Biomarker Development, Almac Diagnostics, Craigavon, UK

15.50 - 16.00 Proffered Paper Presentation

Platinum-resistance in epithelial ovarian cancer (EOC) is dependent on a VEGFa-PDGFR $\alpha$  signalling mechanism that activates downstream angiogenesis pathways

Aya El Helali

CCRCB, Queen's University Belfast, UK

	CCACB, Queen's University Benast, ON	
16:00 - 16:40 Auditorium	Closing of conference: Keeping the promise and preparing for the future	
	Chair: Denis Horgan Executive Director, European Alliance for Personalised Medicine, Bussels, Belgium	
16.00 - 16.05	Jevgeni Ossinovski Minister of Health, Estonia	
16.05 - 16.10	David Byrne Chair European Alliance for Personalised Medicine, Brussels, Belgium	
16.10 - 16.20	Stephen Friend Chairman, Co-Founder and Past President Sage Bionetworks; Leader Health Team, Apple Inc., San Francisco, USA	
16.20 - 16.30	Stanimir Hasurdjiev Secretary-General of the Patient Access Partnership, Brussels, Belgium	
16.30 - 16.40	Gordon McVie Co-Chair EAPM, Brussels, Belgium	
16.40 - 16.50	Tracy Meharg Executive Director, InvestNI, Belfast, UK	
	Next Steps to Realise the Congress Conclusions	
16.50 - 17.00 Auditorium	Denis Horgan  EAPM Executive Director	
	Mark Lawler Chair in Translational Cancer Genomics, Queen's University Belfast, UK	









